Pathology and tumor microenvironment of vestibular schwannoma.

Q2 Medicine

Handbook of clinical neurology Pub Date : 2025-01-01 DOI:10.1016/B978-0-12-824534-7.00014-7

Cathal John Hannan, Aditya Raghunathan, Jamie J Van Gompel, Omar Pathmanaban

{"title":"Pathology and tumor microenvironment of vestibular schwannoma.","authors":"Cathal John Hannan, Aditya Raghunathan, Jamie J Van Gompel, Omar Pathmanaban","doi":"10.1016/B978-0-12-824534-7.00014-7","DOIUrl":null,"url":null,"abstract":"<p><p>Vestibular schwannomas (VS) are WHO Grade 1 tumors arising from the vestibule-cochlear nerve and account for 8% of all intracranial neoplasms. In recent years, there has been a dramatic evolution in how the pathology of these tumors is regarded, and there is emerging interest in the role of the tumor microenvironment. In this chapter, we provide a comprehensive description of the pathology and microenvironment of VS, with a particular focus on the interlinked processes of immune cell infiltration and angiogenesis. Improved understanding of the pathophysiology of these tumors has already yielded therapeutic benefits in the form of bevacizumab for NF2-schwannomatosis-associated VS, and the potential role that immunomodulatory agents may play in the management of these patients will become clearer as our appreciation of the tumor microenvironment improves. Given the morbidity associated with current treatment options for VS, it is incumbent upon researchers to advance our understanding of this area so that we may use this information to develop new therapies and improve the care of our patients.</p>","PeriodicalId":12907,"journal":{"name":"Handbook of clinical neurology","volume":"212 ","pages":"47-57"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of clinical neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/B978-0-12-824534-7.00014-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Vestibular schwannomas (VS) are WHO Grade 1 tumors arising from the vestibule-cochlear nerve and account for 8% of all intracranial neoplasms. In recent years, there has been a dramatic evolution in how the pathology of these tumors is regarded, and there is emerging interest in the role of the tumor microenvironment. In this chapter, we provide a comprehensive description of the pathology and microenvironment of VS, with a particular focus on the interlinked processes of immune cell infiltration and angiogenesis. Improved understanding of the pathophysiology of these tumors has already yielded therapeutic benefits in the form of bevacizumab for NF2-schwannomatosis-associated VS, and the potential role that immunomodulatory agents may play in the management of these patients will become clearer as our appreciation of the tumor microenvironment improves. Given the morbidity associated with current treatment options for VS, it is incumbent upon researchers to advance our understanding of this area so that we may use this information to develop new therapies and improve the care of our patients.

查看原文本刊更多论文

前庭神经鞘瘤的病理与肿瘤微环境。

前庭神经鞘瘤（VS）是起源于前庭-耳蜗神经的WHO一级肿瘤，占所有颅内肿瘤的8%。近年来，人们对这些肿瘤病理的认识发生了巨大的变化，人们对肿瘤微环境的作用越来越感兴趣。在本章中，我们全面描述了VS的病理和微环境，特别关注免疫细胞浸润和血管生成的相互关联过程。对这些肿瘤病理生理学的进一步了解已经以贝伐单抗的形式产生了治疗nf2 -神经鞘瘤病相关VS的益处，随着我们对肿瘤微环境的认识的提高，免疫调节剂在这些患者的治疗中可能发挥的潜在作用将变得更加清晰。鉴于VS的发病率与目前的治疗方案相关，研究人员有责任推进我们对这一领域的理解，以便我们可以利用这些信息开发新的治疗方法并改善患者的护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Handbook of clinical neurology Medicine-Neurology (clinical)

CiteScore

4.10

自引率

0.00%

发文量

302

期刊介绍： The Handbook of Clinical Neurology (HCN) was originally conceived and edited by Pierre Vinken and George Bruyn as a prestigious, multivolume reference work that would cover all the disorders encountered by clinicians and researchers engaged in neurology and allied fields. The first series of the Handbook (Volumes 1-44) was published between 1968 and 1982 and was followed by a second series (Volumes 45-78), guided by the same editors, which concluded in 2002. By that time, the Handbook had come to represent one of the largest scientific works ever published. In 2002, Professors Michael J. Aminoff, François Boller, and Dick F. Swaab took on the responsibility of supervising the third (current) series, the first volumes of which published in 2003. They have designed this series to encompass both clinical neurology and also the basic and clinical neurosciences that are its underpinning. Given the enormity and complexity of the accumulating literature, it is almost impossible to keep abreast of developments in the field, thus providing the raison d''être for the series. The series will thus appeal to clinicians and investigators alike, providing to each an added dimension. Now, more than 140 volumes after it began, the Handbook of Clinical Neurology series has an unparalleled reputation for providing the latest information on fundamental research on the operation of the nervous system in health and disease, comprehensive clinical information on neurological and related disorders, and up-to-date treatment protocols.